{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:58:43Z","timestamp":1790996323100,"version":"4.1.0"},"reference-count":202,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR6806\/GBD\/27\/480\/2012"],"award-info":[{"award-number":["BT\/PR6806\/GBD\/27\/480\/2012"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["SB\/YS\/LS-61\/2014"],"award-info":[{"award-number":["SB\/YS\/LS-61\/2014"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.bbagen.2016.06.018","type":"journal-article","created":{"date-parts":[[2016,6,19]],"date-time":"2016-06-19T07:09:15Z","timestamp":1466320155000},"page":"1989-1997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room"],"prefix":"10.1016","volume":"1860","author":[{"given":"Rajib","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupom","family":"Borah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbagen.2016.06.018_bb0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1586\/14737175.2014.877842","article-title":"The pathomechanisms underlying Parkinson's disease","volume":"14","author":"Jellinger","year":"2014","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0010","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0015","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.pneurobio.2008.05.003","article-title":"Progress in Parkinson's disease \u2014 where do we stand?","volume":"85","author":"Toulouse","year":"2008","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jns.2014.01.002","article-title":"Non-motor symptoms of Parkinson's disease a review \u2026 from the past","volume":"338","author":"Garcia-Ruiz","year":"2014","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bbadis.2011.10.002","article-title":"\u0391-synuclein misfolding and Parkinson's disease","volume":"1822","author":"Breydo","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0030","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.expneurol.2009.09.027","article-title":"Glutamate, excitotoxicity, and programmed cell death in Parkinson disease","volume":"220","author":"Caudle","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0035","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf3634","article-title":"\u03b1-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson's disease","volume":"8","author":"Di Maio","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0040","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM196902132800701","article-title":"Modification of Parkinsonism \u2014 chronic treatment with L-DOPA","volume":"280","author":"Cotzias","year":"1969","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0045","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.pneurobio.2011.06.005","article-title":"L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?","volume":"94","author":"Lipski","year":"2011","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0050","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3389\/fneur.2014.00242","article-title":"Presynaptic mechanisms of L-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications","volume":"5","author":"Cenci","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0055","doi-asserted-by":"crossref","first-page":"534","DOI":"10.2174\/1389202914666131210210559","article-title":"Homocysteine level and mechanisms of injury in Parkinson's disease as related to MTHFR, MTR, and MTHFD1 genes polymorphisms and L-DOPA treatment","volume":"14","author":"Rozycka","year":"2013","journal-title":"Curr. Genom."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1389202914666131210213042","article-title":"Molecular effects of L-DOPA therapy in Parkinson's disease","volume":"15","author":"Dorszewska","year":"2014","journal-title":"Curr. Genom."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0065","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1600-079X.2009.00713.x","article-title":"Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents","volume":"47","author":"Borah","year":"2009","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0070","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.brainres.2010.05.010","article-title":"Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism","volume":"1344","author":"Borah","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0075","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.neuint.2009.11.008","article-title":"L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation","volume":"56","author":"Borah","year":"2010","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/092986710790149774","article-title":"Elevated homocysteine levels in Parkinson's disease: is there anything besides L-DOPA treatment","volume":"17","author":"Zoccolella","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050496","article-title":"Elevated homocysteine by levodopa is detrimental to neurogenesis in parkinsonian model","volume":"7","author":"Shin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ane.12106","article-title":"Elevated homocysteine levels in levodopa-treated idiopathic Parkinson's disease: a meta-analysis","volume":"128","author":"Hu","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0095","first-page":"83","article-title":"The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?","volume":"53","author":"Agid","year":"1990","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1001\/archneurol.2009.32","article-title":"Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease","volume":"66","author":"Parkinson Study Group CALM Cohort Investigators","year":"2009","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0105","first-page":"1","article-title":"Revisiting the medical management of Parkinson's disease: levodopa versus dopamine agonist","volume":"14","author":"Zhang","year":"2015","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/biof.71","article-title":"Homocysteine metabolism and its relation to health and disease","volume":"36","author":"Williams","year":"2010","journal-title":"Biofactors"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0115","first-page":"527","article-title":"Sulfate and cysteine levels in the plasma of patients with Parkinson's disease","volume":"16","author":"Allain","year":"1995","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0120","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1001\/archneur.64.11.1646","article-title":"Mild parkinsonian signs and plasma homocysteine concentration in community-dwelling elderly individuals","volume":"64","author":"Louis","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0125","doi-asserted-by":"crossref","first-page":"19333","DOI":"10.1371\/journal.pone.0019333","article-title":"The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with Parkinson's disease and vascular Parkinsonism","volume":"6","author":"Zhang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0130","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/mds.22482","article-title":"Cysteine elevation in levodopa-treated patients with Parkinson's disease","volume":"24","author":"Muller","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0135","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/1801200a0","article-title":"3.4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists","volume":"180","author":"Carlsson","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0140","first-page":"69","article-title":"Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa\u2013carbidopa associations","volume":"33","author":"Benetello","year":"1993","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0145","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ana.410290516","article-title":"Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease","volume":"29","author":"Olanow","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0150","first-page":"51","article-title":"Long-acting carbidopa\u2013levodopa in the management of moderate and advanced Parkinson's disease","volume":"42","author":"Hutton","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0155","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0022-3565(25)32511-5","article-title":"The site of dopamine formation in rat striatum after L-DOPA administration","volume":"21","author":"Hefti","year":"1981","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0006-8993(95)01281-8","article-title":"Aromatic L-amino acid decarboxylase is present in serotonergic fibers of the striatum of the rat, a double-labeling immunofluorescence study","volume":"706","author":"Arai","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0165","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1046\/j.1471-4159.1999.721516.x","article-title":"Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats","volume":"72","author":"Miller","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0170","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias","volume":"127","author":"de la Fuente-Fern\u00e1ndez","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0175","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1212\/01.wnl.0000242888.30755.5d","article-title":"Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study","volume":"67","author":"Pavese","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0180","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.nbd.2006.01.009","article-title":"Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine","volume":"22","author":"Meissner","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0185","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","article-title":"Levodopa and the progression of Parkinson's disease","volume":"351","author":"Fahn","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0190","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10928-006-9012-6","article-title":"Disease progression and pharmacodynamics in Parkinson's disease evidence for functional protection with levodopa and other treatments","volume":"33","author":"Holford","year":"2006","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0195","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11095-006-9202-3","article-title":"Levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation","volume":"24","author":"Chan","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0200","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1471-4159.2009.06381.x","article-title":"Neuroprotective effect of L-DOPA on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study","volume":"111","author":"Shin","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0205","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1046\/j.1471-4159.1997.69041398.x","article-title":"Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron\/cortical astrocyte cocultures","volume":"69","author":"Mena","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0210","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0026-895X(24)13069-6","article-title":"A synergistic neurotrophic response to L-dihydroxyphenylalanine and nerve growth factor","volume":"54","author":"Mena","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0215","article-title":"Low-dose levodopa protects nerve cells from oxidative stress and up-regulates expression of pCREB and CD39","volume":"9","author":"Zhong","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0220","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00001756-199601310-00016","article-title":"Glia conditioned medium protects fetal rat midbrain neurons in culture from L-DOPA toxicity","volume":"7","author":"Mena","year":"1996","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0225","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.tox.2008.02.007","article-title":"Inhibition of glycogen synthase kinase-3 reduces L-DOPA-induced neurotoxicity","volume":"247","author":"Koh","year":"2008","journal-title":"Toxicology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0230","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.neuro.2011.05.009","article-title":"L-DOPA neurotoxicity is prevented by neuroprotective effects of erythropoietin","volume":"32","author":"Park","year":"2011","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0235","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1471-4159.1989.tb09150.x","article-title":"Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains","volume":"52","author":"Riederer","year":"1989","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0240","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1523\/JNEUROSCI.16-08-02553.1996","article-title":"Astrocytes protect neurons from hydrogen peroxide toxicity","volume":"16","author":"Desagher","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0245","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mds.870080305","article-title":"Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line","volume":"8","author":"Pardo","year":"1993","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0250","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1124\/jpet.102.042267","article-title":"Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress","volume":"304","author":"Mytilineou","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0255","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1212\/WNL.32.6.684","article-title":"Chronic dopa feeding of mice","volume":"32","author":"Reches","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0260","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1471-4159.1984.tb12834.x","article-title":"Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically","volume":"43","author":"Perry","year":"1984","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0265","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.410430504","article-title":"Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions","volume":"43","author":"Murer","year":"1998","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0270","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s702-002-8236-2","article-title":"Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys","volume":"109","author":"Lyras","year":"2002","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0275","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.brainres.2005.09.041","article-title":"L-DOPA administration enhances 6-hydroxydopamine generation","volume":"1063","author":"Maharaj","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0280","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.neuropharm.2012.11.010","article-title":"L-DOPA -induced dopamine synthesis and oxidative stress in serotonergic cells","volume":"67","author":"Stansley","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0285","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0006-8993(95)00341-M","article-title":"Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants","volume":"682","author":"Pardo","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0290","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1046\/j.1471-4159.1995.64020825.x","article-title":"L-DOPA cytotoxicity to PC12 cells in culture is via its autoxidation","volume":"64","author":"Basma","year":"1995","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0295","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1089\/dna.2011.1546","article-title":"Protective effects of L-DOPA and carbidopa combined treatments on human catecholaminergic cells","volume":"31","author":"Colamartino","year":"2012","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0300","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1046\/j.1471-4159.1999.0731155.x","article-title":"Enhancing effect of manganese on L-DOPA-induced apoptosis in PC12 cells: role of oxidative stress","volume":"73","author":"Migheli","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0305","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00001756-200002280-00015","article-title":"L-DOPA -induced neurotoxic and apoptotic changes on cultured chromaffin cells","volume":"11","author":"Corona-Morales","year":"2000","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0310","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0006-8993(95)00988-7","article-title":"Acute L-DOPA pretreatment potentiates 6-hydroxydopamine-induced toxic effects on nigro-striatal dopamine neurons in mice","volume":"701","author":"Naudin","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0315","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mds.870080202","article-title":"Suppressive effect of L-DOPA on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine","volume":"8","author":"Blunt","year":"1998","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0320","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s10571-007-9213-6","article-title":"Long-term L-DOPA treatment causes indiscriminate increase in dopamine levels at the cost of serotonin synthesis in discrete brain regions of rats","volume":"27","author":"Borah","year":"2007","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0325","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.mehy.2012.05.008","article-title":"L-DOPA induced-endogenous 6-hydroxydopamine is the cause of aggravated dopaminergic neurodegeneration in Parkinson's disease patients","volume":"79","author":"Borah","year":"2012","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0330","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12264-013-1330-2","article-title":"Contribution of \u03b2-phenethylamine, a component of chocolate and wine, to dopaminergic neurodegeneration: implications for the pathogenesis of Parkinson's disease","volume":"29","author":"Borah","year":"2013","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0335","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/cns.12113","article-title":"\u03b2-Phenethylamine\u2014a phenylalanine derivative in brain\u2014contributes to oxidative stress by inhibiting mitochondrial complexes and DT-diaphorase: an in silico study","volume":"19","author":"Mazumder","year":"2013","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0340","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.neuint.2015.07.025","article-title":"Cholesterol \u2014 a putative endogenous contributor towards Parkinson's disease","volume":"90","author":"Paul","year":"2015","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0345","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0197-0186(02)00075-X","article-title":"Catechol-O-methyltransferase inhibition protects against 3.4-dihydroxyphenylalanine (DOPA) toxicity in primary mesencephalic cultures: new insights into levodopa toxicity","volume":"42","author":"Blessing","year":"2003","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0350","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1021\/jm00223a008","article-title":"Potential oxidative pathways of brain catecholamines","volume":"19","author":"Tse","year":"1976","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0355","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S0026-895X(25)13536-0","article-title":"Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro","volume":"14","author":"Graham","year":"1978","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0360","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1016\/0006-2952(82)90259-3","article-title":"Conjugation of dopa and 5-S-cysteinyldopa with cysteine mediated by superoxide radical","volume":"31","author":"Ito","year":"1982","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0365","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0028-3908(86)90242-X","article-title":"Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species","volume":"25","author":"Fornstedt","year":"1986","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0370","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0304-3940(90)90404-W","article-title":"A 3.4-dihydroxyphenylalanine oxidation product is a non-N-methyl-d-aspartate glutamatergic agonist in rat cortical neurons","volume":"116","author":"Aizenman","year":"1990","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0375","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1046\/j.1471-4159.1995.64041742.x","article-title":"Iron-mediated oxidation of 3.4-dihydroxyphenylalanine to an excitotoxin","volume":"64","author":"Newcomer","year":"1995","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0380","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1073\/pnas.88.11.4865","article-title":"2,4,5-Trihydroxyphenylalanine in solution forms a non-N-methyl-d-aspartate glutamatergic agonist and neurotoxin","volume":"88","author":"Rosenberg","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0385","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1471-4159.1993.tb03602.x","article-title":"Nonenzymatic conversion of 3.4-dihydroxyphenylalanine to 2,4,5-trihydroxyphenylalanine and 2,4,5-trihydroxyphenylalanine quinone in physiological solutions","volume":"61","author":"Newcomer","year":"1993","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0390","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev.nutr.28.061807.155438","article-title":"Methionine metabolism and liver disease","volume":"28","author":"Mato","year":"2008","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0395","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s00018-008-8516-1","article-title":"Structure-function relationships in methionine adenosyltransferases","volume":"66","author":"Markham","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0400","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1515\/CCLM.2007.341","article-title":"Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine","volume":"45","author":"Finkelstein","year":"2007","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0405","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev.nutr.19.1.217","article-title":"Homocysteine metabolism","volume":"19","author":"Selhub","year":"1999","journal-title":"Annu. Rev. Nutr."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0410","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10545-010-9177-4","article-title":"Overview of homocysteine and folate metabolism. With special references to cardiovascular disease and neural tube defects","volume":"34","author":"Blom","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0415","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1096\/fj.09-143651","article-title":"Regulation of homocysteine metabolism and methylation in human and mouse tissues","volume":"24","author":"Chen","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0420","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/abbi.1997.0246","article-title":"Betaine\u2013homocysteine methyltransferase expression in porcine and human tissues and chromosomal localization of the human gene","volume":"345","author":"Sunden","year":"1997","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0425","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/S0021-9258(18)93829-9","article-title":"Enzymatic synthesis of the methyl group of methionine. VII. Isolation of a cobalamin-containing transmethylase (5-methyltetrahydro-folate-homocysteine) from mammalian liver","volume":"239","author":"Loughlin","year":"1964","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0430","first-page":"107","article-title":"Homocysteine and Parkinson's disease: a complex relationship","volume":"1","author":"Doherty","year":"2013","journal-title":"J. Neurol. Disord."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0435","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.freeradbiomed.2013.05.001","article-title":"Glutathione metabolism and Parkinson's disease","volume":"62","author":"Smeyne","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0440","first-page":"157","article-title":"Synthesis of homocysteine thiolactone in normal and malignant cells","volume":"196","author":"Jakubowski","year":"1997","journal-title":"Homocysteine Metab."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0445","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/j.bbagen.2015.08.013","article-title":"Protein N-homocysteinylation: from cellular toxicity to neurodegeneration","volume":"1850","author":"Sharma","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0450","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1039\/C4AN02355B","article-title":"Crosstalk of homocysteinylation, methylation and acetylation on histone H3","volume":"140","author":"Xu","year":"2015","journal-title":"Analyst"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0455","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMoa060900","article-title":"Heart outcomes prevention evaluation (HOPE) 2 investigators, homocysteine lowering with folic acid and B vitamins in vascular disease","volume":"354","author":"Lonn","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0460","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0021-9150(95)05748-X","article-title":"Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria","volume":"122","author":"Tsai","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0465","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.thromres.2006.05.009","article-title":"Polymorphism C776G in the transcobalamin II gene and homocysteine, folate and vitamin B12 concentrations. Association with MTHFR C677T and A1298C and MTRR A66G polymorphisms in healthy children","volume":"119","author":"Al\u00e9ssio","year":"2007","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0470","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1007\/s11033-011-1008-7","article-title":"Polymorphism C1420T of serine hydroxymethyltransferase gene on maternal risk for Down syndrome","volume":"39","author":"Marucci","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0475","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1021\/bi9730893","article-title":"Methionine synthase exists in two distinct conformations that differ in reactivity toward methyltetrahydrofolate, adenosylmethionine, and flavodoxin","volume":"37","author":"Jarrett","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0480","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0021-9150(00)00739-5","article-title":"The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations","volume":"157","author":"Gaughan","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0485","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1056\/NEJM199905133401901","article-title":"The effect of folic acid fortification on plasma folate and total homocysteine concentrations","volume":"340","author":"Jacques","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0490","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1024\/0301-1526.28.3.151","article-title":"Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis","volume":"28","author":"Wuillemin","year":"1999","journal-title":"Vasa"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0495","doi-asserted-by":"crossref","first-page":"872","DOI":"10.5858\/2007-131-872-HATAO","article-title":"Hyperhomocysteinemia and thrombosis: an overview","volume":"131","author":"Eldibany","year":"2007","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0500","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1001\/archneur.64.11.1646","article-title":"Mild parkinsonian signs and plasma homocysteine concentration in community-dwelling elderly individuals","volume":"64","author":"Louis","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0505","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000007984","article-title":"Elevated plasma levels of homocysteine in Parkinson's disease","volume":"40","author":"Kuhn","year":"1998","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0510","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archneur.61.6.865","article-title":"Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations","volume":"61","author":"O'Suilleabhain","year":"2004","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0515","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1468-1331.2004.00973.x","article-title":"Hyperhomocysteinemia in L-DOPA treated Parkinson's disease patients: effect of cobalamin and folate administration","volume":"12","author":"Lamberti","year":"2005","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0520","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.parkreldis.2004.07.008","article-title":"Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications","volume":"11","author":"Zoccolella","year":"2005","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2016.06.011","article-title":"L-DOPA treatment in MPTP-mouse model of Parkinson's disease potentiates homocysteine accumulation in substantia nigra","author":"Bhattacharjee","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0530","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jocn.2009.09.034","article-title":"L-DOPA therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease","volume":"17","author":"Isobe","year":"2010","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0535","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1212\/01.wnl.0000225050.57553.6d","article-title":"Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease","volume":"67","author":"de Lau","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0540","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1017\/S0007114510001005","article-title":"Fukuoka Kinki Parkinson's Disease Study Group, dietary intake of folate, vitamin B6, vitamin B12 and riboflavin and risk of Parkinson's disease: a case-control study in Japan","volume":"104","author":"Murakami","year":"2010","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0545","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1006\/exnr.1997.6466","article-title":"Levels of l-methionine S-adenosyltransferase activity in erythrocytes and concentrations of S-adenosylmethionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease","volume":"145","author":"Cheng","year":"1997","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0550","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/exnr.2001.7726","article-title":"L-DOPA upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase","volume":"171","author":"Zhao","year":"2001","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0555","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/j.1600-0404.2004.00315.x","article-title":"The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease","volume":"110","author":"Bialecka","year":"2004","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0560","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/FPC.0b013e328306c2f2","article-title":"The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications","volume":"18","author":"Bialecka","year":"2008","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0565","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00702-004-0262-4","article-title":"The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats","volume":"112","author":"Nissinen","year":"2005","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0570","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.parkreldis.2008.10.005","article-title":"Effect of levodopa and entacapone treatment on plasma homocysteine levels in Parkinson's disease patients","volume":"15","author":"Nevrly","year":"2009","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/NDT.S2404","article-title":"COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson's disease (PD): relevance for motor and non-motor features","volume":"4","author":"Antonini","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0580","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00044-015-1472-z","article-title":"Garcinol prevents hyperhomocysteinemia and enhances bioavailability of L-DOPA by inhibiting catechol-O-methyltransferase: an in silico approach","volume":"25","author":"Mazumder","year":"2016","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0585","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.tins.2015.08.003","article-title":"The molecular constituents of the blood\u2013brain barrier","volume":"38","author":"Chow","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0590","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1755-5949.2012.00340.x","article-title":"Tight junction in blood\u2013brain barrier: an overview of structure, regulation, and regulator substances","volume":"18","author":"Liu","year":"2012","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0595","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1053\/euhj.1999.1914","article-title":"Homocysteine and atherothrombosis\u2013mechanisms for injury","volume":"21","author":"Thambyrajah","year":"2000","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0600","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev.med.49.1.31","article-title":"Homocysteine and cardiovascular disease","volume":"49","author":"Refsum","year":"1998","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0605","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00702-004-0154-7","article-title":"Studies on homocysteine plasma levels in Alzheimer's patients. Relevance for neurodegeneration","volume":"112","author":"Agnati","year":"2005","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0610","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2005-06-2506","article-title":"Elevated levels of homocysteine compromise blood\u2013brain barrier integrity in mice","volume":"107","author":"Kamath","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0615","doi-asserted-by":"crossref","first-page":"H13","DOI":"10.1152\/ajpheart.00598.2010","article-title":"Vascular complications of cystathionine beta-synthase deficiency: future directions for homocysteine-to-hydrogen sulfide research","volume":"300","author":"Beard","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0620","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000071002","article-title":"Vitamin B12-B6-folate treatment improves blood\u2013brain barrier function in patients with hyperhomocysteinaemia and mild cognitive impairment","volume":"16","author":"Lehmann","year":"2003","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0625","doi-asserted-by":"crossref","first-page":"H1206","DOI":"10.1152\/ajpheart.00376.2005","article-title":"Homocysteine causes cerebrovascular leakage in mice","volume":"290","author":"Lominadze","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063951","article-title":"Opening of the blood\u2013brain barrier before cerebral pathology in mild hyperhomocysteinemia","volume":"8","author":"Rhodehouse","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0635","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1385\/CBB:43:1:037","article-title":"Homocysteine in microvascular endothelial cell barrier permeability","volume":"43","author":"Tyagi","year":"2005","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0640","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/jcbfm.2014.74","article-title":"Role of microRNA29b in blood\u2013brain barrier dysfunction during hyperhomocysteinemia: an epigenetic mechanism","volume":"34","author":"Kalani","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0645","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/jcbfm.2014.102","article-title":"Ablation of MMP9 gene ameliorates paracellular permeability and fibrinogen\u2013amyloid beta complex formation during hyperhomocysteinemia","volume":"9","author":"Muradashvili","year":"2014","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0650","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s12035-015-9212-4","article-title":"Hydrogen sulfide ameliorates homocysteine-induced Alzheimer's disease-like pathology, blood\u2013brain barrier disruption, and synaptic disorder","volume":"53","author":"Kamat","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0655","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12035-013-8421-y","article-title":"Synergy of homocysteine, microRNA, and epigenetics: a novel therapeutic approach for stroke","volume":"48","author":"Kalani","year":"2013","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0660","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neuro.2005.01.008","article-title":"Effects of homocysteine on the dopaminergic system and behavior in rodents","volume":"26","author":"Lee","year":"2005","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0665","first-page":"47","article-title":"Chronic exposure of homocysteine in mice contributes to dopamine loss by enhancing oxidative stress in nigrostriatum and produces behavioral phenotypes of Parkinson\u2019s disease","volume":"6","author":"Bhattacharjee","year":"2016","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0670","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/glia.20185","article-title":"Activation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons","volume":"51","author":"Huang","year":"2005","journal-title":"Glia"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0675","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/clinchem\/47.6.1102","article-title":"Plasma homocysteine and L-DOPA metabolism in patients with Parkinson disease","volume":"47","author":"Blandini","year":"2001","journal-title":"Clin. Chem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0680","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00002826-199702000-00007","article-title":"Effect of L-DOPA and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats","volume":"20","author":"Miller","year":"1997","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0685","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/dmd.31.3.250","article-title":"Molecular modeling and metabolic studies of the interaction of catechol-O-methyltransferase and a new nitrocatechol inhibitor","volume":"31","author":"Palma","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0690","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0197-0186(95)00042-7","article-title":"The source of brain adenosine outflow during ischemia and electrical stimulation","volume":"27","author":"Latini","year":"1995","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0695","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1471-4159.2001.00607.x","article-title":"Adenosine in the central nervous system: release mechanisms and extracellular concentrations","volume":"79","author":"Latini","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0700","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0197-0186(00)00034-6","article-title":"Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors","volume":"38","author":"Cunha","year":"2001","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0705","first-page":"11","article-title":"Sleep-wake regulation and its impact on working memory performance: the role of adenosine","volume":"5","author":"Reichert","year":"2016","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0710","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neuropharm.2015.11.006","article-title":"Purine nucleosides in neuroregeneration and neuroprotection","volume":"104","author":"Ribeiro","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0715","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0074-7742(05)63007-3","article-title":"Adenosine and brain function","volume":"63","author":"Fredholm","year":"2005","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0720","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1046\/j.1471-4159.2001.00178.x","article-title":"Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways","volume":"76","author":"White","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0725","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.devbrainres.2005.07.011","article-title":"Embryonic cerebellar granule cells are resistant to necrosis induced by homocysteine","volume":"160","author":"Foister","year":"2005","journal-title":"Brain Res. Dev. Brain Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0730","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/02713680903421194","article-title":"Sensitivity of staurosporine induced differentiated RGC-5 to homocysteine","volume":"35","author":"Ganapathy","year":"2010","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0735","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neulet.2006.11.031","article-title":"Neurotoxic effects of homocysteine on cerebellar Purkinje neurons in vitro","volume":"413","author":"Oldreive","year":"2007","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0740","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1474-9728.2004.00086.x","article-title":"Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation","volume":"3","author":"Tjiattas","year":"2004","journal-title":"Aging Cell"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0745","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1523\/JNEUROSCI.22-05-01752.2002","article-title":"Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease","volume":"22","author":"Kruman","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0750","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.neures.2007.12.007","article-title":"Nitric oxide and peroxynitrite signalling triggers homocysteine-mediated apoptosis in trigeminal sensory neurons in vitro","volume":"60","author":"Williams","year":"2008","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0755","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.nbd.2006.06.010","article-title":"Binding of copper is a mechanism of homocysteine toxicity leading to COX deficiency and apoptosis in primary neurons, PC12 and SHSY-5Y cells","volume":"23","author":"Linnebank","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0760","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.3233\/JAD-2012-121378","article-title":"Hyperhomocysteinemia in Alzheimer's disease: the hen and the egg?","volume":"33","author":"Farkas","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0765","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fnbeh.2014.00343","article-title":"Homocysteine levels in schizophrenia and affective disorders-focus on cognition","volume":"8","author":"Moustafa","year":"2014","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0770","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000355292","article-title":"Hyperhomocysteinemia in bipolar depression: clinical and biochemical correlates","volume":"68","author":"Permoda-Osip","year":"2013","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0775","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.psyneuen.2013.04.018","article-title":"Association of serum homocysteine with major depressive disorder: results from a large population-based study","volume":"38","author":"Nabi","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0780","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012244","article-title":"Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial","volume":"5","author":"Smith","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0785","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.nbd.2006.01.005","article-title":"Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels","volume":"22","author":"Pacheco-Quinto","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0790","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2174\/156720510790691326","article-title":"Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer's disease","volume":"7","author":"Zhuo","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0795","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.exger.2009.12.005","article-title":"Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet","volume":"45","author":"Zhuo","year":"2010","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0800","doi-asserted-by":"crossref","first-page":"161","DOI":"10.9734\/BJMMR\/2014\/5206","article-title":"Elevated plasma level of homocysteine is an independent risk factor for peripheral neuropathy","volume":"4","author":"Luo","year":"2014","journal-title":"Br. J. Med. Med. Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0805","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.parkreldis.2013.02.006","article-title":"Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery","volume":"19","author":"M\u00fcller","year":"2013","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0810","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1515\/CCLM.2006.143","article-title":"Elevated plasma homocysteine levels in L-DOPA-treated Parkinson's disease patients with dyskinesias","volume":"44","author":"Zoccolella","year":"2006","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0815","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00726-003-0026-8","article-title":"Homocysteine and oxidative stress","volume":"25","author":"Perna","year":"2003","journal-title":"Amino Acids"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0820","doi-asserted-by":"crossref","first-page":"H2649","DOI":"10.1152\/ajpheart.00548.2005","article-title":"Mechanisms of homocysteine-induced oxidative stress","volume":"289","author":"Tyagi","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0825","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.mehy.2011.09.009","article-title":"Hypothesis: hyperhomocysteinemia is an indicator of oxidant stress","volume":"77","author":"Hoffman","year":"2011","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0830","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.lfs.2015.07.031","article-title":"The potential physiological crosstalk and interrelationship between two sovereign endogenous amines, melatonin and homocysteine","volume":"139","author":"Paul","year":"2015","journal-title":"Life Sci."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0835","doi-asserted-by":"crossref","first-page":"5923","DOI":"10.1073\/pnas.94.11.5923","article-title":"Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor","volume":"94","author":"Lipton","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0840","doi-asserted-by":"crossref","first-page":"301","DOI":"10.55782\/ane-2006-1619","article-title":"Excitotoxic neuronal injury in chronic homocysteine neurotoxicity studied in vitro: the role of NMDA and group I metabotropic glutamate receptors","volume":"66","author":"Zieminska","year":"2006","journal-title":"Acta Neurobiol. Exp. (Wars)"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0845","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-079X.2007.00465.x","article-title":"Melatonin inhibits oxidative stress and apoptosis in fetal brains of hyperhomocysteinemic rat dams","volume":"43","author":"Baydas","year":"2007","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0850","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.0022-3042.2001.00676.x","article-title":"Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease","volume":"80","author":"Duan","year":"2002","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0855","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/WNR.0b013e3282aaa0b4","article-title":"Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture","volume":"18","author":"Imamura","year":"2007","journal-title":"Neuroreport"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0860","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1007-4376(08)60003-9","article-title":"Effect and mechanism of homocysteine on Parkinson's disease induced by 6-OHDA","volume":"22","author":"Xing","year":"2008","journal-title":"J. Nanjing Med. Univ."},{"issue":"1","key":"10.1016\/j.bbagen.2016.06.018_bb0865","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10072-011-0645-x","article-title":"Cognitive and neurochemical alterations in hyperhomocysteinemic rat","volume":"33","author":"Gao","year":"2012","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0870","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/jmf.2009.1278","article-title":"Curcumin exerts neuroprotective effects against homocysteine intracerebroventricular injection-induced cognitive impairment and oxidative stress in rat brain","volume":"13","author":"Ataie","year":"2010","journal-title":"J. Med. Food"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0875","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.brainres.2005.12.073","article-title":"Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats","volume":"1075","author":"Chandra","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0880","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2047-9158-4-3","article-title":"Treatment of the later stages of Parkinson's disease \u2014 pharmacological approaches now and in the future","volume":"4","author":"Jenner","year":"2015","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0885","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/13543784.2012.651457","article-title":"New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors","volume":"21","author":"Blandini","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0890","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40263-012-0016-z","article-title":"Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease","volume":"26","author":"Duty","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0895","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fneur.2014.00144","article-title":"Pharmacological treatments inhibiting levodopa-induced dyskinesias in MPTP-lesioned monkeys: brain glutamate biochemical correlates","volume":"5","author":"Morin","year":"2014","journal-title":"Front. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0900","first-page":"219","article-title":"Chemical pathology of homocysteine. IV. Excitotoxicity, oxidative stress, endothelial dysfunction, and inflammation","volume":"39","author":"McCully","year":"2009","journal-title":"Ann. Clin. Lab. Sci."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0905","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/jnc.12102","article-title":"Novel crosstalk between ERK MAPK and p38 MAPK leads to homocysteine-NMDA receptor-mediated neuronal cell death","volume":"124","author":"Poddar","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0910","doi-asserted-by":"crossref","first-page":"II36","DOI":"10.1007\/PL00007759","article-title":"Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms","volume":"247","author":"Chase","year":"2000","journal-title":"J. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0915","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","article-title":"Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease","volume":"96","author":"Sgambato-Faure","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0920","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.brainresbull.2008.10.004","article-title":"Behavioural effects of a selective NMDA NR1A\/2B receptor antagonist in rats with unilateral 6-OHDA+parafasicular lesions","volume":"78","author":"Truong","year":"2009","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0925","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.nbd.2012.06.009","article-title":"Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease","volume":"48","author":"Quintana","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0930","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbr.2014.12.059","article-title":"NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model","volume":"282","author":"Kong","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0935","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3565(24)35003-7","article-title":"Differing effects of N-methyl-d-aspartate receptor subtype selective antagonists on dyskinesia in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys","volume":"290","author":"Blanchet","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0940","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/mds.20654","article-title":"Prevention of levodopainduced dyskinesias by a selective NR1\/NR2B N-methyl-d-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin","volume":"21","author":"Morissette","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0945","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.neuropharm.2009.06.030","article-title":"Effect of nondopaminergic drug treatment on levodopa induced dyskinesia in MPTP monkeys: common implications of striatal peptides","volume":"58","author":"Tamim","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0950","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.expneurol.2005.08.017","article-title":"Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD","volume":"196","author":"Bibbiani","year":"2005","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0955","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/mds.22917","article-title":"NMDA antagonist memantine improves levodopa-induced dyskinesia and \u201con\u2013off\u201d phenomena in Parkinson's disease","volume":"24","author":"Varanese","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0960","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/mds.23034","article-title":"Long-term antidyskinetic efficacy of amantadine in Parkinson's disease","volume":"25","author":"Wolf","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0965","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/1531-8257(200009)15:5<1016::AID-MDS1042>3.0.CO;2-J","article-title":"The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-DOPA","volume":"15","author":"Hana\u011fasi","year":"2000","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0970","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/mds.22169","article-title":"Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism","volume":"23","author":"Nutt","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0975","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.neurobiolaging.2011.06.019","article-title":"Targeting NR2A containing NMDA receptors reduces L-DOPA -induced dyskinesia","volume":"33","author":"Gardoni","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bbagen.2016.06.018_bb0980","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1471-4159.2009.06207.x","article-title":"Homocysteine-NMDA receptor-mediated activation of extracellular signal-regulated kinase leads to neuronal cell death","volume":"110","author":"Poddar","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0985","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2174\/156802606777057553","article-title":"Survival signaling pathways activated by NMDA receptors","volume":"6","author":"Hetman","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0990","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nn1040","article-title":"Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia","volume":"6","author":"Picconi","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.bbagen.2016.06.018_bb0995","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.neuropharm.2004.11.008","article-title":"Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease","volume":"48","author":"Hallett","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbagen.2016.06.018_bb1000","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1523\/JNEUROSCI.5326-05.2006","article-title":"A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia","volume":"26","author":"Gardoni","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbagen.2016.06.018_bb1005","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1111\/j.1460-9568.2005.04169.x","article-title":"Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets","volume":"21","author":"Hurley","year":"2005","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbagen.2016.06.018_bb1010","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nbd.2003.07.003","article-title":"Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease","volume":"14","author":"Calon","year":"2003","journal-title":"Neurobiol. Dis."}],"container-title":["Biochimica et Biophysica Acta (BBA) - General Subjects"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416516302239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304416516302239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:45:20Z","timestamp":1788295520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304416516302239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":202,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S0304416516302239"],"URL":"https:\/\/doi.org\/10.1016\/j.bbagen.2016.06.018","relation":{},"ISSN":["0304-4165"],"issn-type":[{"value":"0304-4165","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - General Subjects","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbagen.2016.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}